Hartmut Döhner

113.7k total citations · 20 hit papers
653 papers, 44.9k citations indexed

About

Hartmut Döhner is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Hartmut Döhner has authored 653 papers receiving a total of 44.9k indexed citations (citations by other indexed papers that have themselves been cited), including 357 papers in Hematology, 304 papers in Genetics and 224 papers in Molecular Biology. Recurrent topics in Hartmut Döhner's work include Acute Myeloid Leukemia Research (288 papers), Chronic Lymphocytic Leukemia Research (221 papers) and Lymphoma Diagnosis and Treatment (132 papers). Hartmut Döhner is often cited by papers focused on Acute Myeloid Leukemia Research (288 papers), Chronic Lymphocytic Leukemia Research (221 papers) and Lymphoma Diagnosis and Treatment (132 papers). Hartmut Döhner collaborates with scholars based in Germany, United States and United Kingdom. Hartmut Döhner's co-authors include Stephan Stilgenbauer, Konstanze Döhner, Peter Lichter, Lars Bullinger, Clara D. Bloomfield, Richard F. Schlenk, Axel Benner, Daniel J. Weisdorf, Elihu H. Estey and Martin Bentz and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Hartmut Döhner

636 papers receiving 44.1k citations

Hit Papers

Diagnosis and management of acute myeloid leukemia... 1997 2026 2006 2016 2009 2015 2000 2008 2008 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
    2009 2.4k citations Hartmut Döhner, Elihu H. Estey et al. Blood profile →
  2. Acute Myeloid Leukemia
    2015 2.3k citations Hartmut Döhner, Clara D. Bloomfield et al. New England Journal of Medicine profile →
  3. Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
    2000 2.3k citations Hartmut Döhner, Stephan Stilgenbauer et al. New England Journal of Medicine profile →
  4. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
    2008 2.2k citations Michael Hallek, Hartmut Döhner et al. Blood profile →
  5. Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
    2008 1.1k citations Richard F. Schlenk, Konstanze Döhner et al. New England Journal of Medicine profile →
  6. Acute myeloid leukaemia
    2006 992 citations Elihu H. Estey, Hartmut Döhner profile →
  7. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
    2018 971 citations Michael Hallek, Hartmut Döhner et al. Blood profile →
  8. Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia
    2004 703 citations Lars Bullinger, Konstanze Döhner et al. New England Journal of Medicine profile →
  9. Matrix-based comparative genomic hybridization: Biochips to screen for genomic imbalances
    1997 699 citations Stephan Stilgenbauer, Axel Benner et al. profile →
  10. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
    2002 660 citations Richard F. Schlenk, Axel Benner et al. Blood profile →
  11. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
    2008 605 citations Miguel Á. Sanz, David Grimwade et al. Blood profile →
  12. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission
    2009 604 citations Richard F. Schlenk, Jorge Sierra et al. profile →
  13. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
    2005 603 citations Konstanze Döhner, Richard F. Schlenk et al. Blood profile →
  14. V H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia
    2002 597 citations Axel Benner, Lars Bullinger et al. Blood profile →
  15. High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
    2009 596 citations Bob Löwenberg, Gert J. Ossenkoppele et al. New England Journal of Medicine profile →
  16. IDH1andIDH2Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1Mutation WithoutFLT3Internal Tandem Duplication
    2010 578 citations Richard F. Schlenk, Jan Krönke et al. Journal of Clinical Oncology profile →
  17. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
    2017 331 citations Lars Bullinger, Konstanze Döhner et al. Journal of Clinical Oncology profile →
  18. Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia
    2022 295 citations Andre C. Schuh, Hartmut Döhner et al. New England Journal of Medicine profile →
  19. Towards precision medicine for AML
    2021 174 citations Hartmut Döhner, Andrew H. Wei et al. profile →
  20. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
    2024 47 citations Hartmut Döhner, Andrew H. Wei et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hartmut Döhner Germany 101 21.1k 19.0k 17.5k 12.1k 9.5k 653 44.9k
Donna Neuberg United States 113 12.4k 0.6× 9.4k 0.5× 14.4k 0.8× 11.3k 0.9× 9.5k 1.0× 719 46.3k
Francis J. Giles United States 105 20.4k 1.0× 15.8k 0.8× 15.0k 0.9× 6.3k 0.5× 4.6k 0.5× 786 41.9k
Clara D. Bloomfield United States 91 28.5k 1.4× 12.1k 0.6× 17.7k 1.0× 5.3k 0.4× 3.6k 0.4× 406 42.9k
Brian Druker United States 106 30.5k 1.4× 21.7k 1.1× 17.1k 1.0× 3.9k 0.3× 5.8k 0.6× 607 54.8k
Moshe Talpaz United States 98 29.2k 1.4× 22.8k 1.2× 11.0k 0.6× 4.6k 0.4× 4.6k 0.5× 778 44.8k
Guillermo Garcia‐Manero United States 106 30.6k 1.4× 14.7k 0.8× 17.8k 1.0× 4.0k 0.3× 3.9k 0.4× 1.5k 44.1k
Daniel Catovsky United Kingdom 83 14.6k 0.7× 19.4k 1.0× 7.2k 0.4× 13.6k 1.1× 10.3k 1.1× 529 35.2k
William G. Wierda United States 88 11.0k 0.5× 18.2k 1.0× 8.5k 0.5× 13.0k 1.1× 8.2k 0.9× 829 31.7k
Frederick R. Appelbaum United States 105 30.9k 1.5× 8.9k 0.5× 9.8k 0.6× 4.3k 0.4× 7.0k 0.7× 595 42.6k
Jörge E. Cortes United States 139 60.4k 2.9× 41.4k 2.2× 23.6k 1.4× 9.3k 0.8× 6.4k 0.7× 2.3k 85.0k

Countries citing papers authored by Hartmut Döhner

Since Specialization
Citations

This map shows the geographic impact of Hartmut Döhner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hartmut Döhner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hartmut Döhner more than expected).

Fields of papers citing papers by Hartmut Döhner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hartmut Döhner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hartmut Döhner. The network helps show where Hartmut Döhner may publish in the future.

Co-authorship network of co-authors of Hartmut Döhner

This figure shows the co-authorship network connecting the top 25 collaborators of Hartmut Döhner. A scholar is included among the top collaborators of Hartmut Döhner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hartmut Döhner. Hartmut Döhner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Menezes, Daniel L., Andrew H. Wei, Hartmut Döhner, et al.. (2023). P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL. HemaSphere. 7(S3). e930876b–e930876b. 1 indexed citations
3.
Roboz, Gail J., Farhad Ravandi, Andrew H. Wei, et al.. (2022). Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood. 139(14). 2145–2155. 37 indexed citations
4.
Ng, Yuen Lam Dora, Evelyn Ramberger, Stephan Bohl, et al.. (2022). Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nature Communications. 13(1). 1009–1009. 42 indexed citations
5.
6.
Bullinger, Lars, Konstanze Döhner, & Hartmut Döhner. (2017). Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. Journal of Clinical Oncology. 35(9). 934–946. 331 indexed citations breakdown →
7.
Engert, Andreas, Anneke Brand, Bertrand Coiffier, et al.. (2016). The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica. 101(2). 115–208. 46 indexed citations
8.
Tausch, Eugen, R. Schlenk, Peter Hillmen, et al.. (2014). SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911). Haematologica. 99. 522–523. 1 indexed citations
9.
Bień, Barbara, et al.. (2013). Disabled older people's use of health and social care services and their unmet care needs in six European countries. European Journal of Public Health. 23(6). 1032–1038. 49 indexed citations
10.
Oakes, Christopher C., Rainer Claus, Lei Gu, et al.. (2013). Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia. Cancer Discovery. 4(3). 348–361. 110 indexed citations
11.
Bloehdorn, Johannes, Martin Sill, Christian Langer, et al.. (2013). High CD52 mRNA Expression Is An Adverse Prognostic Factor In Fludarabine-Refractory CLL Treated With Alemtuzumab On The Gcllsg CLL2H Trial. Blood. 122(21). 1618–1618. 1 indexed citations
12.
Bullinger, Lars, Richard F. Schlenk, Marlies Götz, et al.. (2013). PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17). Clinical Cancer Research. 19(9). 2562–2571. 31 indexed citations
13.
Kovaleva, Valentina, Rodrígo Mora, Yoon Jung Park, et al.. (2012). miRNA-130a Targets ATG2B and DICER1 to Inhibit Autophagy and Trigger Killing of Chronic Lymphocytic Leukemia Cells. Cancer Research. 72(7). 1763–1772. 161 indexed citations
14.
Kvinlaug, Brynn T., Lars Bullinger, Mukundhan Ramaswami, et al.. (2011). Common and Overlapping Oncogenic Pathways Contribute to the Evolution of Acute Myeloid Leukemias. Cancer Research. 71(12). 4117–4129. 37 indexed citations
15.
16.
Langer, Christian, et al.. (2010). Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Experimental Hematology. 38(12). 1126–1130. 114 indexed citations
17.
Döhner, Hartmut, Elihu H. Estey, Sergio Amadori, et al.. (2009). Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115(3). 453–474. 2350 indexed citations breakdown →
18.
Zenz, Thorsten, Andrea Schnaiter, Daniel Mertens, et al.. (2009). A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia. Cancer Research. 69(23). 8977–8986. 45 indexed citations
19.
Eichhorst, Barbara, Raymonde Busch, Stephan Stilgenbauer, et al.. (2009). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 114(16). 3382–3391. 238 indexed citations
20.
Schlenk, Richard F., Konstanze Doehner, & Hartmut Döhner. (2008). Cytogenetically normal acute myeloid leukemia - Reply. New England Journal of Medicine. 359(6). 652–653. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donna Neuberg Breakdown of academic impact, for papers by Francis J. Giles Breakdown of academic impact, for papers by Clara D. Bloomfield Breakdown of academic impact, for papers by Brian Druker Breakdown of academic impact, for papers by Moshe Talpaz Breakdown of academic impact, for papers by Guillermo Garcia‐Manero Breakdown of academic impact, for papers by Daniel Catovsky Breakdown of academic impact, for papers by William G. Wierda Breakdown of academic impact, for papers by Frederick R. Appelbaum Breakdown of academic impact, for papers by Jörge E. Cortes
Rankless by CCL
2026